Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 41 articles: HTML format

Single Articles

September 2025
1. LEE H, Kim D, Kim B, Joung D, et al
   UDP-glucose ceramide glucosyltransferase promotes radioresistance via membrane reorganization to maintain redox balance in glioblastoma.
   Br J Cancer. 2025 Sep 22. doi: 10.1038/s41416-025-03191.
   PubMed     Abstract available
   
   
   July 2025
2. GE Y, Yu M, Chang T, Wang Z, et al
   Predictive efficacy and role of 2HG in MGMT promoter methylation in gliomas: a retrospective study based on MRS and mediator variable analysis.
   Br J Cancer. 2025 Jul 30. doi: 10.1038/s41416-025-03132.
   PubMed     Abstract available
   
   
   
3. ERJAN A, Jamora K, Gutierrez E, Santiago A, et al
   Cumulative incidence and survival outcomes of brain metastases in sarcoma: a large single center retrospective analysis.
   Br J Cancer. 2025 Jul 26. doi: 10.1038/s41416-025-03111.
   PubMed     Abstract available
   
   
   
4. TANG S, Qu C, Zhang M, Zhou P, et al
   Novel mutations of SRPX facilitate the stemness and malignant progression of glioma.
   Br J Cancer. 2025 Jul 15. doi: 10.1038/s41416-025-03091.
   PubMed     Abstract available
   
   
   
5. LU VM, Chandar JS, Castro JR, Seetharam D, et al
   Elucidating the association between TLR-4 expression and the clinical course of glioblastoma leptomeningeal disease.
   Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03094.
   PubMed     Abstract available
   
   
   June 2025
6. YANG R, Wang M, Zhang G, Bao Y, et al
   Correction: E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression.
   Br J Cancer. 2025 Jun 20. doi: 10.1038/s41416-025-03057.
   PubMed    
   
   
   May 2025
7. ZHANG Z, Jin X, Yin Q, Li P, et al
   Cyst fluid ctDNA as a biomarker for genetic profiling and treatment monitoring in cystic brain metastases.
   Br J Cancer. 2025 May 29. doi: 10.1038/s41416-025-03047.
   PubMed     Abstract available
   
   
   April 2025
8. WANG Z, Zou P, Chen Z, Hou J, et al
   Novel strategy to target glioblastoma-initiating cells using a braintropic adeno-associated virus carrying a miR-dependent genome-editing system.
   Br J Cancer. 2025 Apr 12. doi: 10.1038/s41416-025-03007.
   PubMed     Abstract available
   
   
   
9. PU Y, Xu F, He A, Li R, et al
   Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy.
   Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992.
   PubMed     Abstract available
   
   
   March 2025
10. STRASSHEIMER F, Elleringmann P, Ludmirski G, Roller B, et al
    CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.
    Br J Cancer. 2025 Mar 18. doi: 10.1038/s41416-025-02977.
    PubMed     Abstract available
    
    
    
11. STEINDL A, Zach C, Berchtold L, Grisold A, et al
    Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.
    Br J Cancer. 2025 Mar 1. doi: 10.1038/s41416-025-02967.
    PubMed     Abstract available
    
    
    October 2024
12. SERRA R, Smith SJ, Rowlinson J, Gorelick N, et al
    Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma.
    Br J Cancer. 2024 Oct 22. doi: 10.1038/s41416-024-02878.
    PubMed     Abstract available
    
    
    September 2024
13. ZHANG ZS, Gao ZX, He JJ, Ma C, et al
    Andrographolide sensitizes glioma to temozolomide by inhibiting DKK1 expression.
    Br J Cancer. 2024 Sep 12. doi: 10.1038/s41416-024-02842.
    PubMed     Abstract available
    
    
    
14. SEIBOLDT T, Zeiser C, Nguyen D, Celikyurekli S, et al
    Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
    Br J Cancer. 2024;131:763-777.
    PubMed     Abstract available
    
    
    August 2024
15. ROA P, Foglizzo V, Harada G, Repetto M, et al
    Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Br J Cancer. 2024;131:601-610.
    PubMed     Abstract available
    
    
    June 2024
16. QI L, Du Y, Huang Y, Kogiso M, et al
    CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas.
    Br J Cancer. 2024 Jun 4. doi: 10.1038/s41416-024-02724.
    PubMed     Abstract available
    
    
    May 2024
17. YANG L, Yi J, He W, Kong P, et al
    Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673.
    PubMed     Abstract available
    
    
    February 2024
18. CAO Q, Hajosch A, Kast RE, Loehmann C, et al
    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02608.
    PubMed     Abstract available
    
    
    
19. CHIANG JY, Wei ST, Chang HJ, Chen DC, et al
    ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signalling.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02581.
    PubMed     Abstract available
    
    
    
20. PRETE AA, Angerilli V, Bergamo F, Vettore V, et al
    HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-023-02569.
    PubMed     Abstract available
    
    
    
21. MOGENSEN H, Tettamanti G, Frederiksen LE, Talback M, et al
    Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden.
    Br J Cancer. 2024;130:260-268.
    PubMed     Abstract available
    
    
    
22. FLECCHIA C, Auclin E, Alouani E, Mercier M, et al
    Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
    Br J Cancer. 2024;130:442-449.
    PubMed     Abstract available
    
    
    January 2024
23. HEYMER EJ, Hawkins MM, Winter DL, Teepen JC, et al
    Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
    Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02577.
    PubMed     Abstract available
    
    
    
24. HALLAL SM, Tuzesi A, Sida LA, Xian E, et al
    Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a 'liquid gold' biopsy.
    Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02548.
    PubMed     Abstract available
    
    
    
25. JOO JE, Chu YL, Georgeson P, Walker R, et al
    Intratumoral presence of the genotoxic gut bacteria pks(+) E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer.
    Br J Cancer. 2024 Jan 10. doi: 10.1038/s41416-023-02554.
    PubMed     Abstract available
    
    
    November 2023
26. TRIVEDI R, Bhat KP
    Liquid biopsy: creating opportunities in brain space.
    Br J Cancer. 2023;129:1727-1746.
    PubMed     Abstract available
    
    
    October 2023
27. THOMAS EM, Wright JA, Blake SJ, Page AJ, et al
    Advancing translational research for colorectal immuno-oncology.
    Br J Cancer. 2023;129:1442-1450.
    PubMed     Abstract available
    
    
    September 2023
28. VANDERLINDEN A, Jones CG, Myers KN, Rominiyi O, et al
    DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.
    Br J Cancer. 2023 Sep 30. doi: 10.1038/s41416-023-02454.
    PubMed     Abstract available
    
    
    
29. CHENG S, McLaughlin JR, Brown MC, Al-Sawaihey H, et al
    Correction: Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada.
    Br J Cancer. 2023 Sep 13. doi: 10.1038/s41416-023-02415.
    PubMed    
    
    
    
30. HVIDTFELDT UA, Chen J, Rodopoulou S, Strak M, et al
    Long-term air pollution exposure and malignant intracranial tumours of the central nervous system: a pooled analysis of six European cohorts.
    Br J Cancer. 2023;129:656-664.
    PubMed     Abstract available
    
    
    August 2023
31. NTAFOULIS I, Kleijn A, Ju J, Jimenez-Cowell K, et al
    Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
    Br J Cancer. 2023 Aug 24. doi: 10.1038/s41416-023-02402.
    PubMed     Abstract available
    
    
    
32. ZHAN Y, Song Y, Qiao W, Sun L, et al
    Focused ultrasound combined with miR-1208-equipped exosomes inhibits malignant progression of glioma.
    Br J Cancer. 2023 Aug 14. doi: 10.1038/s41416-023-02393.
    PubMed     Abstract available
    
    
    
33. PARK J, Shim JK, Lee M, Kim D, et al
    Classification of IDH wild-type glioblastoma tumorspheres into low- and high-invasion groups based on their transcriptional program.
    Br J Cancer. 2023 Aug 9. doi: 10.1038/s41416-023-02391.
    PubMed     Abstract available
    
    
    July 2023
34. LOPEZ J, Lai-Kwon J, Molife R, Welsh L, et al
    A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02356.
    PubMed     Abstract available
    
    
    June 2023
35. ZHANG G, Zhu Q, Fu G, Hou J, et al
    Correction to: TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
    Br J Cancer. 2023 Jun 19. doi: 10.1038/s41416-023-02305.
    PubMed    
    
    
    May 2023
36. CHENG S, McLaughlin JR, Brown MC, Al-Sawaihey H, et al
    Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada.
    Br J Cancer. 2023 May 10. doi: 10.1038/s41416-023-02281.
    PubMed     Abstract available
    
    
    
37. CROMIE KJ, Hughes NF, Milner S, Crump P, et al
    Socio-economic and ethnic disparities in childhood cancer survival, Yorkshire, UK.
    Br J Cancer. 2023;128:1710-1722.
    PubMed     Abstract available
    
    
    April 2023
38. LYU L, Jiang Y, Ma W, Li H, et al
    Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-gamma-induced tumour-associated fibroblasts remodelling.
    Br J Cancer. 2023;128:1117-1133.
    PubMed     Abstract available
    
    
    March 2023
39. KIANG KM, Tang W, Song Q, Liu J, et al
    Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.
    Br J Cancer. 2023 Mar 17. doi: 10.1038/s41416-023-02225.
    PubMed     Abstract available
    
    
    February 2023
40. WALLACE ND, Dunne MT, McArdle O, Small C, et al
    Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial.
    Br J Cancer. 2023;128:576-585.
    PubMed     Abstract available
    
    
    September 2022
41. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.